🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 therapy in patients over 65 — July 2024

GLP-1 therapy in patients over 65 — July 2024

andrew_nyc Thu, Jan 9, 2025 at 4:10 AM 9 replies 1,617 viewsPage 1 of 2
This thread is more than 14 months old. Information may be outdated. Consider searching for more recent discussions.
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Jan 9, 2025 at 5:35 AM#1

GLP-1 therapy in patients over 65 — July 2024

I've written this guide because I keep seeing the same questions come up about GLP-1 therapy in patients over 65. Rather than repeating myself across threads, here's everything in one place.

Who this is for: Anyone interested in glp-1 therapy in patients over 65, whether you're a newcomer or looking to deepen your understanding.

1. Overview

GLP-1 therapy in patients over 65 is an important topic in the public square space. Understanding the fundamentals will help you make more informed decisions and have better conversations with your healthcare provider.

2. What the evidence says

The clinical trial data is extensive. Multiple randomized controlled trials (STEP, SURMOUNT, SUSTAIN, SURPASS programs) have established clear efficacy and safety benchmarks. I'll reference specific data points throughout this guide.

3. Practical recommendations

  • Start with the basics — don't overcomplicate things early on
  • Track your own data systematically (weight, labs, side effects)
  • Consult your healthcare provider before making any changes
  • Use this community as a supplement to — not a replacement for — professional medical care

4. Common mistakes

The most common errors I see: rushing titration, inadequate protein intake, not getting baseline labs, and relying on anecdotal reports over clinical data.

This guide is educational. It does not constitute medical advice. Last updated March 2026.

— andrew_nyc | Public Square
34 15Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 31 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Jan 9, 2025 at 5:52 AM#2

To answer the question about GLP-1 therapy in patients over 65 July 2024 — in my experience this comes down to a few key factors.

I have been dealing with this for almost 2 years now, and what I have found is that individual responses really do vary. That said, the general consensus on GLP-1 therapy in patients over seems solid.

What specifically worked for me: combining medication with structured exercise. I would suggest andrew_nyc try the same approach and reporting back.

Last edited: Jan 9, 2025 at 7:52 AM
5 6PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 2 others
Reply Quote Save Share Report
JessicaM_2024
Member
823
3,456
Mar 2024
Portland, OR
Jan 9, 2025 at 6:09 AM#3

Dr.MetabolicMD nailed it. Building on that — GLP-1 therapy in patients over 65 is something I discuss with my PCP regularly, and their clinical perspective aligns with what Dr.MetabolicMD described.

One thing I would add: the first few weeks are not representative of long-term results.

Last edited: Jan 9, 2025 at 7:09 AM
19 23mike_mealprep, NicoleRaleigh, james_edin and 16 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Jan 9, 2025 at 6:26 AM#4

Subscribing to this thread. GLP-1 therapy in patients is exactly what I've been researching. 🙏

Last edited: Jan 9, 2025 at 7:26 AM
17 8rachel_ABQ, traveltech_sara, AttorneyGrant and 14 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Jan 9, 2025 at 6:43 AM#5

Clinical perspective on GLP-1 therapy in patients over 65 July:

I have managed ~150 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that proper titration prevents most adverse events.

For this specific question, I would recommend: reviewing the relevant clinical guidelines.

Last edited: Jan 9, 2025 at 10:43 AM
29 19dan_philly, MeganSA_TX, LarryQC_SD and 26 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register